article thumbnail

STAT+: As pharmaceutical companies bemoan Medicare’s drug negotiations, hospitals and doctors stay mum

STAT

The American Health Care Association, which lobbies on behalf of nursing homes, did not comment on the list of 10 drugs or Medicare’s negotiating power. The Federation of American Hospitals offered no statement.

article thumbnail

Economics and risks of FDA’s Quality management maturity rating programme

European Pharmaceutical Review

Can continuous manufacturing add shareholder value for pharmaceutical companies? The current state of the pharmaceutical market is characterised by an asymmetric information problem that introduces several market imperfections. Quality rating and private-prices: Evidence from the Nursing Home Industry.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

One world, one health: The interconnected web of antimicrobial resistance

pharmaphorum

Nursing homes, dialysis centres, and long-term acute care hospitals all see considerable misuse and overuse of antimicrobials among patients who are, by definition, immunocompromised or infirm.”.

article thumbnail

Is Donanemab a Breakthrough Against Alzheimer’s?

The People's Pharmacy

Most importantly, will this anti-amyloid drug keep people out of nursing homes? Pharmaceutical companies do not know what to make of this unexpected complication. We will have to see more data to better understand the meaning of this clinical trial. Will the drug restore memory? Another problem is brain shrinkage.

article thumbnail

Q&A: As RSV vaccine approvals loom, regulators need to devise vaccination strategies

Pharmaceutical Technology

After a long period of inactivity in RSV vaccine development , two pharmaceutical companies are now approaching regulatory decisions for their RSV vaccines. GAVI has created a market for the pharmaceutical companies to be able to develop enough doses for these LMIC markets.